Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05092360 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
A Phase 3 study, sponsored by Mural Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT05092360 is a Phase 3 study that was terminated before completion, run by Mural Oncology. The registered enrollment target is 456 participants.
The verdict
NCT05092360, a Phase 3 study, was terminated before completion, sponsored by Mural Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Paclitaxel
- DRUG Pegylated Liposomal Doxorubicin (PLD)
- BIOLOGICAL Nemvaleukin and Pembrolizumab Combination
- BIOLOGICAL Nemvaleukin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05092360
The ClinicalTrials.gov registry entry for NCT05092360 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mural Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05092360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05092360 about?
NCT05092360 is a clinical study titled "Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)". This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
What is the current status of trial NCT05092360?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2022-01-10. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT05092360?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Paclitaxel (DRUG), Pegylated Liposomal Doxorubicin (PLD) (DRUG), Nemvaleukin and Pembrolizumab Combination (BIOLOGICAL), Nemvaleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05092360?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.